Chinese firms look to compete in domestic breast cancer market
As China seeks to increase its population size, another priority is to combat diseases prevalent in its population, such as human epidermal growth factor receptor 2-negative/hormone receptor-positive breast cancer (HER2-/HR+ BC).
Foreign firms have historically dominated the HER2-/HR+ market in China. However, change is on the horizon as multiple domestic companies are developing late-stage products.
According to GlobalData’s Pharmaceutical Intelligence Center, China accounts for 27% of the global HER2-/HR+ BC cases, with the number of incident cases by biomarker expected to grow at an annual growth rate of 3.36% from 381,844 in 2022 to 445,616 in 2028. Some argue that this is directly linked to China's aging population, with old age being a key risk factor for BC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze